文献速递类风湿关节炎脊柱关节炎

托法替布对类风湿关节炎和银屑病关节炎患者残留疼痛的影响

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis.
PubMed 文献 · RMD Open · 2022-01-01

该研究汇总9项随机对照试验数据,事后分析托法替布对炎症已消退的类风湿关节炎(RA)或银屑病关节炎(PsA)患者残留疼痛的影响。治疗3个月后炎症消退者中,托法替布或阿达木单抗组第3个月残留疼痛视觉模拟评分(VAS)中位数低于安慰剂组,PsA患者中差异不如RA明显,贝叶斯网络Meta分析显示托法替布与阿达木单抗之间无显著差异。

要点

  • 治疗3个月后炎症消退比例:托法替布组14.9%(382/2568)、阿达木单抗组17.1%(118/691)、安慰剂组5.5%(50/909)。
  • RA患者第3个月残留疼痛VAS中位数:托法替布17.0、阿达木单抗19.0、安慰剂33.5。
  • PsA患者第3个月残留疼痛VAS中位数:托法替布24.0、阿达木单抗21.0、安慰剂27.0。

核心结论

  • 炎症已消退的RA/PsA患者中,托法替布或阿达木单抗组第3个月残留疼痛降低幅度大于安慰剂组。
  • 托法替布与阿达木单抗之间结果相似。

研究设计与样本

  • 对9项随机对照试验汇总数据的事后分析。
  • 纳入接受至少1剂托法替布5 mg每日两次、阿达木单抗或安慰剂(联用或不联用背景传统合成改善病情抗风湿药)且治疗3个月后炎症消退(肿胀关节计数SJC=0且C反应蛋白CRP<6 mg/L)的患者。

主要发现

  • 总人群中治疗3个月后炎症消退比例:托法替布组14.9%(382/2568)、阿达木单抗组17.1%(118/691)、安慰剂组5.5%(50/909)。
  • 炎症消退的RA/PsA患者中,托法替布/阿达木单抗组基线CRP高于安慰剂组;RA患者中托法替布/阿达木单抗组SJC更低、病程更长。
  • RA患者第3个月残留疼痛VAS中位数:托法替布17.0、阿达木单抗19.0、安慰剂33.5。
  • PsA患者第3个月残留疼痛VAS中位数:托法替布24.0、阿达木单抗21.0、安慰剂27.0。
  • 贝叶斯网络Meta分析显示,托法替布/阿达木单抗与安慰剂相比的残留疼痛降低在PsA患者中不如RA患者明显,托法替布与阿达木单抗之间无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Post hoc analysis of pooled data from nine randomised controlled trials to assess the effect of tofacitinib (oral Janus kinase inhibitor for treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA)) on residual pain in patients with RA or PsA with abrogated inflammation. METHODS: Patients who received ≥1 dose of tofacitinib 5 mg twice daily, adalimumab or placebo with/without background conventional synthetic disease-modifying antirheumatic drugs and had abrogated inflammation (swollen joint count (SJC)=0 and C reactive protein (CRP)<6 mg/L) after 3 months' therapy were included. Assessments included Patient's Assessment of Arthritis Pain at month 3 (Visual Analogue Scale [VAS] 0-100 mm). Scores were summarised descriptively; treatment comparisons assessed by Bayesian network meta-analyses (BNMA). RESULTS: From the total population with RA/PsA, 14.9% (382 of 2568), 17.1% (118 of 691) and 5.5% (50 of 909) of patients receiving tofacitinib, adalimumab and placebo, respectively, had abrogated inflammation after 3 months' therapy. Patients with RA/PsA with abrogated inflammation receiving tofacitinib/adalimumab had higher baseline CRP versus placebo; patients with RA receiving tofacitinib/adalimumab had lower SJC and longer disease duration versus placebo. Median residual pain (VAS) at month 3 was 17.0, 19.0 and 33.5 in patients with RA treated with tofacitinib, adalimumab or placebo, and 24.0, 21.0 and 27.0 in patients with PsA, respectively. Residual pain reductions with tofacitinib/adalimumab versus placebo were less prominent in patients with PsA versus patients with RA, with no significant differences between tofacitinib/adalimumab, per BNMA. CONCLUSION: Patients with RA/PsA with abrogated inflammation receiving tofacitinib/adalimumab had greater residual pain reduction versus placebo at month 3. Results were similar between tofacitinib and adalimumab. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov registry (NCT00960440; NCT00847613; NCT00814307; NCT00856544; NCT00853385; NCT01039688; NCT02187055; NCT01877668; NCT01882439).

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Dougados M, Taylor PC, Bingham CO, et al. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD Open. 2022. PMID: 36814062. doi:10.1136/rmdopen-2022-002478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。